Multiple Sclerosis Serum

About Multiple Sclerosis Serum

Human Multiple Sclerosis Serum for Neuroimmunology and Neurodegeneration Research

Our Multiple Sclerosis Serum is sourced from IRB-consented donors clinically diagnosed with multiple sclerosis (MS). Each sample is processed and frozen within 24 hours of collection to preserve neuroaxonal damage markers, immunoglobulins, cytokines, and viral serology for neuroimmunology research.

Why Serum for Multiple Sclerosis Research

MS is an immune-mediated, autoimmune demyelinating disease of the central nervous system driven by autoreactive T cells and B cells that cross the blood–brain barrier. It is not a classical autoantibody-mediated disease — no single pathogenic autoantibody defines it — and serum is valuable for a different reason: it now carries validated markers of the tissue damage the immune attack produces.

• Serum neurofilament light chain — sNfL is the best-established blood biomarker of ongoing neuroaxonal injury in MS, and its measurement in serum has largely replaced the need for cerebrospinal fluid for this purpose
• Glial injury markers — serum GFAP reflects astroglial pathology and is of particular interest in progressive disease
• Serum is required to exclude MS mimics — anti-aquaporin-4 and anti-MOG antibody testing on serum distinguishes neuromyelitis optica spectrum disorder and MOG antibody–associated disease from MS, which makes serologically characterised MS cohorts genuinely valuable
• Paired serum is needed for intrathecal synthesis — oligoclonal bands and the IgG index are cerebrospinal fluid findings that can only be interpreted against a simultaneous serum sample, so serum is not optional in CSF-based MS work
• Epstein–Barr virus serology — anti-EBNA1 antibody responses are among the most strongly established environmental risk associations in MS, and are measured in serum
• Therapy monitoring analytes — anti-drug antibodies against disease-modifying therapies and JC virus antibody status for risk stratification are serum-based measurements central to treatment research

Donor Stratification Available

• Disease course — relapsing-remitting, secondary progressive, or primary progressive MS
• Disability level — EDSS score where recorded
• Clinical state at draw — active relapse versus clinical remission
• Disease-modifying therapy — treatment-naive, or on interferon beta, glatiramer acetate, fumarate, S1P receptor modulator, natalizumab, or anti-CD20 therapy
• Disease duration and radiological activity — time since diagnosis, and MRI lesion activity where available
• Paired specimen availability — matched cerebrospinal fluid from the same donor where collected
• Matched healthy controls available — demographically matched healthy donor serum

Product Features

• Collected from clinically confirmed MS donors
• Processed and frozen within 24 hours of collection
• Research Use Only (RUO)
• Standard and custom aliquot volumes available
• IRB-approved protocols with documented consent

De-identified Donor Data

• Diagnosis confirmation and disease course where classified
• Age, sex assigned at birth, and ethnicity
• Donor-reported allergy, medication, and infectious disease history
• Disease-modifying therapy history and clinical values available on request

Applications

• Serum neurofilament light chain and GFAP measurement and assay development
• Neuroaxonal damage and disease progression biomarker discovery
• Anti-AQP4 and anti-MOG serology for differential diagnosis research
• Paired serum and CSF studies of intrathecal immunoglobulin synthesis
• Epstein–Barr virus and viral risk-factor serology
• Cytokine, chemokine, and inflammatory protein profiling
• Disease-modifying therapy response, anti-drug antibody, and JCV risk research
• Therapeutic candidate screening and validation

Other Multiple Sclerosis Specimen Types

Matched material from the same MS donor pool is available as multiple sclerosis plasma, whole blood, PBMC, leukopak, and cerebrospinal fluid. Course-specific cohorts are available as relapsing-remitting MS serum and secondary progressive MS serum.

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
• Documentation support available for regulatory review

Ordering & Customization

Multiple sclerosis serum is available in standard and custom volumes. For pricing, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To browse the full specimen range and healthy-donor controls, see our human serum collection.